Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.64 - $3.31
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$4.23M
Enterprise Value-$433.86K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.36
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding6,080,920
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap-0.10
Enterprise Value/Revenue-0.05
Enterprise Value/Gross Profit-0.07
Enterprise Value/Ebitda0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Balance-sheet RepairRecent reduction in total debt and a swing to positive equity materially improve solvency compared with prior years. This strengthens the company’s ability to withstand near-term shocks, preserves strategic optionality for licensing or M&A, and reduces immediate refinancing pressure.
Opaganib Regulatory ProgressRare pediatric disease designation and orphan status increase potential regulatory and commercial advantages, including eligibility for priority pathways or a priority review voucher. This raises opaganib's strategic value in oncology and could attract partners or non-dilutive funding if clinical benefit is confirmed.
Commercial Portfolio & PartnershipsRestructuring Talicia into a co-commercial vehicle and securing Cumberland partnership plus expanded Humana Part D and ex-U.S. licensing diversifies revenue channels. These deals reduce single-product concentration and leverage partners' commercial reach to stabilize recurring product sales.
Bears Say
Severe Revenue DeclineA near-complete collapse of product revenue undermines the company's commercial base and makes operating leverage ineffective. Sustained top-line deterioration erodes pricing power, weakens negotiating position with partners, and makes multi-year investment in trials and commercialization harder to fund internally.
Persistent Cash BurnConsistently large negative operating cash flows indicate structural failure to generate cash from operations. Ongoing burn forces dependence on external financing, constrains R&D timelines and acquisition execution, and raises execution risk for clinical programs and commercialization plans.
Reliance On Dilutive FinancingExpanded ATM capacity and recent private placements show heavy reliance on equity markets for liquidity. That dependence creates dilution risk and, coupled with Nasdaq minimum-bid pressure and listing risk, narrows strategic options and may increase the cost of raising future capital.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.64 and its highest was $3.31 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $4.23M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 20, 2026 which is in 37 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 6,080,920 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational compounds. RHB-204 is currently in Phase 3 for pulmonary nontuberculous mycobacteria infections. Opaganib (Yeliva), an SK2 selective inhibitor, has completed Phase 2 for severe SARS-CoV-2 related COVID-19 pneumonia, is in Phase 2 for advanced unresectable cholangiocarcinoma, and is also being investigated in a researcher-sponsored Phase 2 study for prostate cancer. RHB-107 is progressing through Phase 2/3 trials for COVID-19 outpatients, is undergoing preclinical evaluation for advanced unresectable cholangiocarcinoma, and has successfully concluded Phase 2 studies for gastrointestinal and other solid tumors. Furthermore, RHB-104 is in Phase 3 development for Crohn's disease. RHB-102 (Bekinda) is also in Phase 3 for acute gastroenteritis and gastritis, following its successful completion of Phase 2 for irritable bowel syndrome with diarrhea. Lastly, RHB-106, an encapsulated formulation designed for bowel preparation, is preparing to commence Phase 2/3 clinical studies. Established in 2009, RedHill Biopharma Ltd. maintains its headquarters in Tel Aviv, Israel.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---